Pharmacotherapy of the overactive bladder and advances in drug delivery.
Cannon
Tracy Washington
TW
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Chancellor
Michael B
MB
D000283:Administration, Intravesical; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D002211:Capsaicin / Q000494:pharmacology / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D003408:Cresols / Q000494:pharmacology / Q000627:therapeutic use; D018856:Cystitis, Interstitial / Q000188:drug therapy; D004224:Diterpenes / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008333:Mandelic Acids / Q000494:pharmacology; D009498:Neurotoxins / Q000494:pharmacology / Q000627:therapeutic use; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D001743:Urinary Bladder / Q000187:drug effects; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy*
D000929:Antidepressive Agents, Tricyclic; D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D004224:Diterpenes; D008333:Mandelic Acids; D009498:Neurotoxins; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C024353:resiniferatoxin; D001905:Botulinum Toxins; C005419:oxybutynin; D002211:Capsaicin